Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ei Gains License to Sphingolipids | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ei Gains License to Sphingolipids

Expands skincare technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ei, A Pharmaceutical SolutionWorks, has signed agreements with European-based professors and technologists for the exclusive worldwide license of a novel class of sphingolipids. Sphingolipids are thought to play a critical role in strengthening the barrier function of the skin, promoting moisture retention and increasing elasticity of the skin. Ei has been granted options on several related technologies in various stages of development.
 
In preliminary clinical studies, the technology demonstrated significantly better barrier function with substantial improvement in moisture retention when compared to commercially available sphingolipid compounds. 
 
“As A Pharmaceutical SolutionWorks, this investment in intellectual property demonstrates Ei’s mission to offer our customers value beyond typical development and manufacturing capability,” said Michael Kane, chief executive officer of Ei. “Our customers have asked for unique, efficacious and highly protected ways to innovate for their customers and enhance the value of their brands.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters